Trial of an SGLT-2 Inhibitor in Patients with Heart Failure and Valvular Disease

Dapagliflozin was safe and reduced HF events soon after transcatheter aortic valve replacement in an older cohort, but it did not improve survival.

Sodium–glucose cotransporter-2 (SGLT-2) inhibitors reduce hospitalizations related to heart failure (HF) in high-risk patients. To assess the efficacy of SGLT-2 inhibition in patients with HF and valvular disease, researchers randomized patients with HF and aortic stenosis undergoing transcatheter aortic valve replacement (TAVR) in Spain to receive dapagliflozin (10 mg/day) or standard care alone, in open-label fashion (NCT04696185).

The primary analysis included 1222 patients (mean age, 82 years; 49% women; mean pre-TAVR aortic valve gradient, 47 mm Hg); 44% had diabetes, 88% moderate renal insufficiency, and 17% left-ventricular systolic dysfunction. Baseline use of HF medical therapies was similar in the two randomized groups. Approximate…

Reviewing Author

Shea E. Hogan, MD, MSCS, FACC, FSCAI, FSVM

Disclosures

Editorial BoardsVascular Medicine

Shea E. Hogan, MD, MSCS, FACC, FSCAI, FSVM

Disclosures

Editorial BoardsVascular Medicine

Trial of an SGLT-2 Inhibitor in Patients with Heart Failure and Valvular Disease

Topics

Reviewing Author